Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Sep 12, 2019 (7 years ago)

Natpara (parathyroid hormone)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Natpara (parathyroid hormone) for Injection, 100 mcg, 2 pack medication cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NPS Pharmaceuticals, Inc., Lexington, MA 68875-0205-02

Affected NDC 68875-0205-02

Compare with the code on your package — it is the most precise check available.

Drug: Thyroid

Recalling firm
Shire Human Genetic Therapies, Inc.
Origin
MA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0038-2020 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Thyroid recalls

See all
Class II · Moderate risk

Thyroid

Subpotent Drug

Ongoing Wrong potency / content Specialty Process Labs LLC NDC 81305-100-02 D-0294-2026
Class II · Moderate risk

S.P Labs

Failed Stability Specifications

Completed Stability / shelf life Specialty Process Labs LLC D-0447-2024
Class II · Moderate risk

S.P.Labs

Failed Stability Specifications

Completed Stability / shelf life Specialty Process Labs LLC NDC 81305-500-01 D-0446-2024

Other recalls by Shire Human Genetic Therapies, Inc.

All 2019 recalls
Class I · High risk

Natpara (parathyroid hormone)

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Terminated Packaging defect Shire Human Genetic Therapies, Inc. NDC 68875-0204-02 D-0037-2020
Class I · High risk

Natpara (parathyroid hormone)

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Terminated Packaging defect Shire Human Genetic Therapies, Inc. NDC 68875-0203-02 D-0036-2020
Class I · High risk

Natpara (parathyroid hormone)

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Terminated Packaging defect Shire Human Genetic Therapies, Inc. NDC 68875-0202-02 D-0035-2020